Literature DB >> 22921736

The switch between relapse and remission in multiple sclerosis: continuous inflammatory response balanced by Th1 suppression and neurotrophic factors.

Michael Gurevich1, Anat Achiron.   

Abstract

Multiple sclerosis (MS) is characterized in most patients by a relapsing-remitting disease course. However, the trigger of relapse and the transformation that switches relapse into remission are not clearly understood. To evaluate the key molecular pathways operating in MS relapse and remission we performed peripheral blood gene-expression profiling in 123 MS patients either in relapse (n=34) or remission (n=89) and in comparison with 41 matched healthy subjects using Affymetrix microarray technology. Our findings suggest that the relapsing-remitting pattern of MS is an ongoing process where inflammation is persistently active in the background of a changing magnitude of processes associated with TBX21-mediated immune suppression and activation of BDNF-related neuroprotection.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22921736     DOI: 10.1016/j.jneuroim.2012.07.014

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  9 in total

1.  Blood RNA profiling in a large cohort of multiple sclerosis patients and healthy controls.

Authors:  Dorothee Nickles; Hsuan P Chen; Michael M Li; Pouya Khankhanian; Lohith Madireddy; Stacy J Caillier; Adam Santaniello; Bruce A C Cree; Daniel Pelletier; Stephen L Hauser; Jorge R Oksenberg; Sergio E Baranzini
Journal:  Hum Mol Genet       Date:  2013-06-06       Impact factor: 6.150

2.  Celecoxib Exerts a Therapeutic Effect Against Demyelination by Improving the Immune and Inflammatory Microenvironments.

Authors:  Peipei Cao; Hao Zhang; Huiling Meng; Yajia Cheng; Haiqi Xu; Siwen Zang; Zongjin Li; Jianlin Cui; Yuhao Li
Journal:  J Inflamm Res       Date:  2020-12-01

Review 3.  Antigen Presentation, Autoantigens, and Immune Regulation in Multiple Sclerosis and Other Autoimmune Diseases.

Authors:  Christine Riedhammer; Robert Weissert
Journal:  Front Immunol       Date:  2015-06-17       Impact factor: 7.561

4.  Bioinformatics Analyses Determined the Distinct CNS and Peripheral Surrogate Biomarker Candidates Between Two Mouse Models for Progressive Multiple Sclerosis.

Authors:  Seiichi Omura; Fumitaka Sato; Nicholas E Martinez; Ah-Mee Park; Mitsugu Fujita; Nikki J Kennett; Urška Cvek; Alireza Minagar; J Steven Alexander; Ikuo Tsunoda
Journal:  Front Immunol       Date:  2019-03-19       Impact factor: 7.561

5.  Genetic polymorphisms and epigenetic regulation of survivin encoding gene, BIRC5, in multiple sclerosis patients.

Authors:  Dariush Rahban; Forogh Mohammadi; Mehdi Alidadi; Taha Ghantabpour; Pedram Abbasi Ghasem Kheyli; Majid Ahmadi
Journal:  BMC Immunol       Date:  2019-08-22       Impact factor: 3.615

6.  Treatment With CD52 Antibody Protects Neurons in Experimental Autoimmune Encephalomyelitis Mice During the Recovering Phase.

Authors:  Wenlin Hao; Qinghua Luo; Michael D Menger; Klaus Fassbender; Yang Liu
Journal:  Front Immunol       Date:  2021-12-16       Impact factor: 7.561

Review 7.  A Brief Overview on BDNF-Trk Pathway in the Nervous System: A Potential Biomarker or Possible Target in Treatment of Multiple Sclerosis?

Authors:  Giuseppe Schirò; Salvatore Iacono; Paolo Ragonese; Paolo Aridon; Giuseppe Salemi; Carmela Rita Balistreri
Journal:  Front Neurol       Date:  2022-07-12       Impact factor: 4.086

8.  Cerebrospinal fluid detection of interleukin-1β in phase of remission predicts disease progression in multiple sclerosis.

Authors:  Silvia Rossi; Valeria Studer; Caterina Motta; Giorgio Germani; Giulia Macchiarulo; Fabio Buttari; Raffaele Mancino; Maura Castelli; Valentina De Chiara; Sagit Weiss; Gianvito Martino; Roberto Furlan; Diego Centonze
Journal:  J Neuroinflammation       Date:  2014-02-18       Impact factor: 8.322

9.  SncRNA (microRNA &snoRNA) opposite expression pattern found in multiple sclerosis relapse and remission is sex dependent.

Authors:  Maider Muñoz-Culla; Haritz Irizar; Matías Sáenz-Cuesta; Tamara Castillo-Triviño; Iñaki Osorio-Querejeta; Lucía Sepúlveda; Adolfo López de Munain; Javier Olascoaga; David Otaegui
Journal:  Sci Rep       Date:  2016-02-01       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.